Rare cases of peripheral T-cell lymphomas with follicular growth pattern (PTCL-F) have been recently reported, and their association with t(5;9)(q33;q22) involving ITK and SYK has been suggested. However, the clinicopathologic aspects of PTCL-F are poorly described and the normal cell counterpart of this subgroup of lymphoma is still unknown. Therefore, we analyzed the pathologic, phenotypic, and cytogenetic features of a series of 30 patients (range: 33 to 88 y) that showed histopathologic features of PTCL-F in at least 1 biopsy (n = 30), either at initial presentation (n = 26) or at relapse (n = 4). Neoplastic cells were medium-sized clear cells that were CD4 + (24/27, 89%), CD10 + (21/29, 72%), BCL-6 + (14/19, 74%), and expressed programed death-1 (27/27, 100%), CXCL13 (23/27, 85%), and ICOS (11/11, 100%), markers of follicular helper T cells (T FH ). Four of 22 patients (18%) had t(5;9)(q33;q22) detected by fluorescence in situ hybridization. Patients with clinical data available had multiple lymphadenopathies (25/28, 89%), stage III to IV diseases (17/26, 65%), B symptoms (7/27, 26%), and skin lesions (6/23, 26%). Three patients with sequential biopsies disclosed clinical and histopathologic features of angioimmunoblastic T-cell lymphoma at initial presentation. Our results show that this rare form of PTCL-F (1) has an immunophenotype indicative of derivation from T FH cells, (2) is associated with t(5;9) in a proportion of cases, and (3) shows some overlapping features with angioimmunoblastic T-cell lymphoma, raising the question of a possible relationship.
P eripheral T-cell lymphomas (PTCL) comprise around 12% of all non-Hodgkin lymphomas in Western countries. Among PTCL, those with a nodal presentation, include 2 well-defined clinicopathologic entities, angioimmunoblastic T-cell lymphomas (AITL), and ALK-positive anaplastic large cell lymphomas (ALCL). 36 The other cases are classified as either ALK-negative ALCL, or more frequently, peripheral T-cell lymphomas, unspecified (PTCL-u). Most cases of PTCL-u involve lymph nodes in a diffuse pattern and it was suggested that most PTCL-u were derived from CD4 + central memory T cells 13 or activated peripheral T cells. 28 However, de Leval et al 7 recently reported 3 cases of PTCL-u with follicular involvement, and some cases with perifollicular growth pattern or involving the mantle zone have been described in other case reports. 16, 32 Recently, Streubel et al 35 reported a novel t(5;9)(q33;q22) translocation in 5 of 30 PTCL-u, including 3 with follicular growth pattern and 1 with perifollicular involvement. However, as for most PTCL, the normal cell counterpart of these PTCL with follicular involvement (PTCL-F) is unknown, and it is not established whether these PTCL-F represent a distinct subtype or a morphologic variant showing overlap with other PTCL-u or AITL. In this respect, previous reports pointed out the common CD4 + /CD10 + / BCL-6 + phenotype of these PTCL-F, resembling that described in AITL, an entity which is now thought to be derived from a peculiar minor subset of T cells, designated follicular B helper T cells (T FH ) 8, 11, 14, 21, 42 and shows a morphologic spectrum from cases demonstrating hyperplastic follicles to those with a diffuse pattern. 1 In this study, we aimed to investigate a series of PTCL-u with follicular growth pattern (PTCL-F) to describe their pathologic and clinical aspects, to determine their normal cell counterpart, and to attempt to approach their possible relationship with AITL.
MATERIALS AND METHODS

Case Selection
Forty specimens (lymph nodes = 36, skin = 2, nasopharynx = 2) from 30 patients were retrieved from the files of Departments of Pathology at Centre Hospitalo-Universitaire Henri Mondor in Cre´teil (n = 22, 14 patients), at Centre Hospitalo-Universitaire de Nantes (n = 12, 10 patients), and at Vienna General Hospital (n = 6, 6 patients) during the period from 1994 to 2007. All patients had a diagnosis of PTCL-F either at diagnosis (n = 26) or at relapse (n = 4). Parts of clinical, histologic, immunohistochemical, and genetic data of 5 patients have already been reported in 2 earlier publications. 29, 35 Each biopsy was reviewed by at least 3 of the 4 hematopathologists (P.G., A.M., Y.H., and A.C.). Although none of the 30 samples classified as PTCL-F fulfilled the complete morphologic and phenotypic criteria of the recognized patterns of AITL, 1 special attention was given to the presence of the following features of AITL, such as neoplastic clear cells, vascular hyperplasia, polymorphous cellular infiltrates including eosinophils and plasma cells, and scattered B immunoblasts. Cases had been previously stained with a panel of antibodies, directed against B (CD20) and T-cell markers (CD2, CD3, CD5, CD7, CD4, and CD8) and a follicular growth pattern had been demonstrated by staining follicular dendritic cells (FDC) with CD23 and/or CNA.42 antibodies and mantle zone B cells with IgD.
Immunohistochemical Studies
Immunohistochemistry was performed on deparaffinized tissue sections using a 3-step immunoperoxidase technique (for all antibodies except CXCL13). After antigen retrieval either with 1 mM ethylenediaminetetraacetic acid buffer at pH 8.0 (DakoCytomation, Glostrup, Denmark) in a water bath for 40 minutes (for most antibodies) or with 1 Â citrate buffer at pH 6 (Diapath, Martinengo, Italy) in a 750 W microwave oven for 15 minutes (for CXCL13), sections were stained for CD2, CD4, CD5, CD7, CD10, CD23, and CD57 (Novocastra, Newcastle, UK); CD3, CD8, CD20, CNA.42, IgD, and BCL-6 (DakoCytomation, Glostrup, Denmark) and CXCL13 (53610, R&D Systems, Minneapolis, MN) antigens. PD-1 was produced by one of the authors (G.R.). 31 For CXCL13, a tyramide signal amplification system (CSAII kit, DakoCytomation) was applied as previously described. 11 ICOS staining was performed by one of the authors (T.M.). 24 
Epstein-Barr Virus (EBV) Studies
The detection of EBV-infected cells was performed using either immunohistochemistry with a monoclonal antibody to LMP-1 (CS1-4, DakoCytomation) or in situ hybridization (ISH) with fluorescein-conjugated EBV (EBERs 1 and 2) oligonucleotides (DakoCytomation, Glostrup, Denmark) complementary to nuclear RNA portions of the EBER 1 and 2 genes. The ISH procedure was performed on deparaffinized tissue sections, as previously reported. 19 
Clonality Analysis
Twenty specimens from 17 patients were investigated for clonality analysis. DNA was extracted from tumor samples using High Pure PCR Template Preparation Kit (Roche, Mannheim, Germany). T-cell receptor g chain gene rearrangements were studied by using a GCclamp multiplex PCR-g-DGGE procedure as previously described 37, 38 and the immunoglobulin (Ig) gene rearrangements by using consensus primers from European BIOMED-2 concerted action. 41 
Fluorescence In Situ Hybridization (FISH) Study
FISH study was performed on deparaffinized tissue sections according to the protocol described previously. 35 The following bacterial artificial clones were selected to identify ITK-SYK rearrangements: RP11-563G12 and RP11-1091N2 flanking ITK for ITK translocations, RP11-31B18 and RP11-47O12 flanking SYK for SYK translocations, and RP11-956N15 and CTB4E7 spanning ITK and SYK for ITK-SYK translocations. Bacterial artificial clone probes were directly labeled with Spec-trumOrange and SpectrumGreen-dUTP using nick translation (Vysis). Twenty-four specimens from 23 patients were studied with all above-mentioned clones. For interphase FISH, 300 cells were analyzed. The cutoff value for the diagnosis of each set of probes was the mean percentage of cells with a false-positive signal constellation plus 3 SDs as assessed with the use of tissue specimens obtained from 10 reactive lymph nodes.
RESULTS
Clinical Characteristics of PTCL-F
Sixteen patients were male and 14 were female. Median age was 67 years (range: 33 to 88). Among the patients with clinical data available, the clinical presentation seems similar to what is usually observed in nodal forms of PTCL (data are given at the time of the first episode with PTCL-F histology): 25/28 patients (89%) had multiple lymphadenopathies, 6/27 (22%) splenomegaly, 7/27 (26%) presented with B symptoms (ie, fever, weight loss, or night sweats), and 6/23 patients (26%) had skin rash or other skin lesions. Most patients (17/26, 65%) had disseminated, Ann Arbor stage III or IV disease. Eight of 23 patients (35%) had an elevated lactate dehydrogenase level at diagnosis. Interestingly, some patients presented with peculiar biologic features characteristic for PTCL, and AITL in particular: hypergammaglobulinemia (5/23, 22%), eosinophilia (1/21, 5%), or a positive Coombs test (6/12, 50%). Owing to the retrospective nature of this study including many referral cases, treatments given were heterogeneous and follow-up data were not available for all patients, making it difficult to draw any firm conclusion on therapeutic results in these patients. Among 23 patients with available data regarding response to treatment (which ranged from oral alkylating-agent monotherapy to high-dose chemotherapy with stem cell support), 20 (87%) eventually showed at least a partial response to treatment, the others being refractory. At the time of last follow-up, 11 patients died of their disease or disease-related complications after a median follow-up of 24 months, 13 were alive including 7 disease-free (follow-up ranging from 12 to 87 mo, median 35 mo) and 6 patients were lost to follow-up. Four patients reached a persistent complete remission after multiagent, anthracyclin-based chemotherapy, lasting for as long as 5 years.
Among the 7 patients with sequential biopsies, 3 (nos. 8, 15, and 30) had clinical and biologic features of AITL at initial presentation-that is multiple lymphadenopathies, splenomegaly, B symptoms, hypergammaglobulinemia, eosinophilia, or a positive Coombs test.
Histopathologic Features of PTCL-F
Among the 40 biopsies from these 30 patients, 30 disclosed features of PTCL with follicular growth pattern ( Table 1) . Among those 30 samples with a diagnosis of PTCL-F (Figs. 1A-F), neoplastic cells in 8 samples were found to be confined within sharply demarcated lymphoid follicles with attenuated mantle zones or marginal zones, responsible of a pattern mimicking follicular lymphoma (FL-like). However, unlike centrocytes, neoplastic cells displayed round or slightly irregular, medium-sized nuclei, with usually abundant cytoplasm. The 22 remaining samples predominantly showed large, regular, or irregular nodules reminiscent of progressive transformation of germinal centers (PTGC-like). These nodules were composed of mature IgD+ B lymphocytes admixed with small aggregates of neoplastic cells displaying medium-sized nuclei with abundant clear cytoplasm. In 5 of these samples (nos. 9, 11, 21, 23, and 28), a mixed FL-like and PTGC-like pattern was present. Three and clinical features of AITL (nos. 8, 15, and 30), but at relapse showed PTCL-F (Figs. 1G-H). Another patient (no. 4) presenting with skin rash, disclosed polymorphous skin infiltrate consistent with cutaneous lesions in AITL at first diagnosis, but the axillary lymph node biopsy 3 years later revealed a PTCL-F with a FL-like pattern. Among the 3 remaining patients, 1 patient (no. 13) with PTCL-F in the first biopsy at diagnosis relapsed as skin lesions with diffuse, haphazard infiltrates of lymphoma cells suggestive of AITL, and the other 2 patients (nos. 5 and 12) with PTCL-F in the first lymph node biopsies then relapsed with a T-cell lymphoma showing features of PTCL-F associated with areas reminiscent of AITL in the second lymph node biopsies 4 and 14 years later, respectively ( Table 2 ).
Immunohistochemical Findings of PTCL-F
Neoplastic cells were T cells with a CD2 + (22/22, 100%), CD3 + (29/29, 100%), CD5 + (21/21, 100%) phenotype with a common loss of CD7 (5/23, 22%) and frequent expression of CD10 (21/29, 72%) and of T FH markers [PD-1 + (27/27, 100%), CXCL13 + (23/27, 85%), BCL-6 + (14/19, 74%), CD57 + (4/19, 21%), ICOS + (11/11, 100%)]. A CD4 + helper T-cell immunophenotype was demonstrated in 24 of the 27 studied cases (89%). All 3 CD4 À cases were also negative for CD8. The 11 cases investigated for expression of TIA1 and/or Granzyme B cytotoxic proteins were negative. Two of the 9 cases investigated for CD25 antigen disclosed heterogeneous staining on neoplastic cells. Presence of scattered CD20 + B-immunoblasts was scored in 13/23 cases (56%) in the vicinity of the atypical T cells and a few EBV-positive cells in 13/19 cases (68%). In addition, a population of small IgD+ B lymphocytes surrounding the neoplastic cells was evidenced in 14 cases. With respect to the 3 newly described T FH markers CXCL13, 11, 14 PD-1, 31 and ICOS, 20 CXCL13 was found to be positive in 23 of the 27 interpretable specimens with a cytoplasmic and/or dotlike staining whereas PD-1 disclosed membrane postivity on neoplastic cells of all 27 interpretable specimens and ICOS in the all 11 tested cases. The growth pattern was often highlighted by the aid of CXCL13, PD-1, and/or ICOS staining. Between these 3 T FH markers, PD-1, and ICOS usually stained more neoplastic cells, often with a sheet-like pattern, than did CXCL13.
Genotypic Findings
T-cell receptor g rearrangement analysis was performed in 20 specimens from 17 patients. Among the 16 patients with interpretable results, 14 patients were found to be clonal, including 1 case disclosing, in addition to a predominant clone, oligoclonal bands (no. 21). Clonality could be investigated in consecutive biopsies of 2 patients (nos. 8 and 15) showing identical bands in the consecutive biopsies. Five of the 6 cases (nos. 9, 10, 13-first, 16, and 21) investigated for immunoglobulin gene rearrangement were polyclonal, the remaining (nos. 12-second) showing an oligoclonal pattern, without any evidence of composite B-cell lymphoma under microscopic examination.
FISH Findings
FISH for t(5;9)(q33;q22) was performed in 24 biopsies from 23 patients. One (no. 3) failed due to lack of signal. Among the 22 patients with adequate signals, 4 patients (18%) were found to have t(5;9)(q33;q22) ( Fig. 1I) , including 2 patients previously reported. 35 One additional patient (no. 29) was investigated by conventional cytogenetics and it was negative for t(5;9). Among the 4 patients positive for t(5;9), 1 (no. 20) presented with symptoms-intense pruritus, general weakness, multiple lymphadenopathy, hemolytic anemia, and splenomegaly-known to be associated with AITL. Another patient (no. 5) was investigated by FISH in 2 consecutive biopsies: this patient initially presented as a disseminated disease with multiple lymphadenopathies showing PTCL-F (FL-like) and recurred 4 years later as a stage II disease with some areas reminiscent of AITL in addition to features of PTCL-F. Translocation t(5;9) was demonstrated on both episodes.
DISCUSSION
We here report a series of 30 patients with peripheral T-cell lymphomas showing a follicular growth pattern, the largest so far reported. We describe their morphologic spectrum and show their immunophenotype that is highly suggestive of derivation from T FH cells. Based on several observations including that of some patients with consecutive biopsies, we suggest their possible relationship with AITL.
Peripheral T-cell lymphomas with a nodular growth pattern have been recently recognized and regarded as part of the morphologic spectrum of PTCL-u. To the best of our knowledge, around 30 cases have been reported 3, 7, 15, 16, 18, 23, 29, 32, 34, 39, 40 that have variable morphologic appearance. In fact, several of these cases have been referred as PTCL with either ''follicular'' or ''perifollicular'' involvement, comprising cases in which neoplastic cells seem to localize within the germinal center, and other cases where neoplastic cells are distributed within the marginal zone with a so-called perifollicular distribution or involve expanded mantle zones of the follicles. Interestingly, most cases have been reported to derive from helper CD4 + T cells, 7, 16, 32 with frequent expression of BCL-6 and CD10 7, 15, 16, 18, 34 and many cases have been reported to be associated with FDC network. 7, 16, 18, 34, 40 It is yet unknown whether these variants represent the morphologic spectrum of the same disease. In the present series, we emphasized that PTCL with follicular growth pattern include cases resembling those previously described by de Leval et al 7 By definition, all cases disclosed a peculiar distribution of neoplastic cells within the germinal center and/or mantle zone of the B-cell follicles, therefore, suggesting a possible derivation from T FH cells. Thus, we investigated by immunohistochemistry the expression of several T FH markers (CD10, CD57, BCL-6, CXCL13, PD-1, ICOS). In addition to the frequent expression of CD10, CD57, BCL-6 in agreement with previous reports, we demon-strate here expression of CXCL13, PD-1, and/or ICOS-3 characteristic T FH markers recently shown to be applicable in diagnostic practice-in all 27 evaluable cases of PTCL-F. 3, 9, 11, 25, 26, 30, 31 This profile strongly supports that the T FH cell can be regarded as the normal cell counterpart of these lymphomas. CXCL13 is a chemokine that promotes follicular homing by B and T cells as well as the migration of a subset of dendritic cells into B-cell follicles in a lymphotoxin-dependent fashion. 46 Originally designated as B-cell-attracting chemokine 1 (BCA1), it interacts with its receptor, CXCR5, to help follicular homing process. In view of these functions, its secretion by neoplastic T FH cells could explain the capacity to induce follicular structures with frequent expansion of IgD small lymphocytes together with that of FDC in PTCL-F. Programed death-1 (PD-1) and inducible costimulator (ICOS) are members of the CD28 family of receptors that also includes CD28, cytotoxic T-lymphocyte-associated antigen 4 and B and T-lymphocyte attenuator. 9 These receptors play a role in the cellular immune response. These molecules play an important role in T-cell-dependent antibody responses and are expressed at very high levels on T FH cells within the light zone of germinal centers. 5, 33 Recently, several reports described that CXCL13, PD-1, and ICOS are overexpressed in T FH cells as well as in AITL not only at the transcriptional level 6,8 but also at the protein level as documented by immunohistochemistry. 11, 14, 24, 25, 31 It is questionable whether there might be some overlap between those PTCL-F and some variants of AITL. AITL is a distinct entity characterized by systemic manifestations including B symptoms, multiple lymphadenopathies, skin rash, effusions, arthritis, typically associated with polyclonal hypergammaglobulinemia, and autoimmune manifestations. 25 However, the constellation of clinical and biologic symptoms seen in the classic form of AITL is not present in every patient 25 and the diagnosis of AITL-at least in its classic form-can rely on a combination of morphologic, immunohistochemical, and/or molecular criteria. 2 AITL has peculiar pathologic features with a diffuse polymorphous infiltrate including variable proportions of medium-sized neoplastic cells associated with prominent arborizing blood vessels, proliferation of FDC, and the presence of EBVpositive large B-cell blasts. 10, 17 Detection of markers such as CD10 or T FH molecules may help. 1, 9, 11, 14, 31 In a recent study, we have shown its molecular link with T FH (Ref. 7) , a finding further confirmed by Piccaluga et al, 27 therefore, strongly supporting its derivation from the minor T FH cell population. By contrast, PTCL-u is regarded as a diagnosis of exclusion. 36 Therefore, this latter category is recognized as heterogeneous and may include cases with overlapping features with other T-cell lymphoma entities, 43 as recently suggested at the molecular level between PTCL-u and AITL. 8, 27, 28 In most of the previous studies, PTCL-F has been included in the category of PTCL-u. Contrary to AITL, they do not show a diffuse effacement of the architecture, lack polymorphous infiltrate in most cases, and had not been so far reported to have the clinical and biologic features typical of AITL. From these previous reports, most patients seem to present with multiple lymphadenopathies, disseminated stage III to IV diseases, and frequent B symptoms, but the presence of skin lesions and biologic manifestations such as hypergammaglobulinemia and autoimmune hemolytic anemia were not recorded. However, in addition to the common expression of CD10 and BCL-6 in a proportion of cases, it is noteworthy that proliferation of high endothelial venules was noted in several reports 7, 16, 32 and marked plasmacytosis, presence of large B-immunoblasts, and/or EBV-positive scattered cells have been reported. 32, 34 In our study, we emphasize these previous pathologic overlapping findings with AITL: the neoplastic cells in PTCL-F have medium-sized nuclei and abundant clear cytoplasm, are frequently admixed with occasional large immunoblasts, and also scattered EBV-positive blasts in a proportion of cases. In addition, despite the fact that complete clinical and biologic data could not be recorded for all patients, some clinical and biologic characteristics of AITL such as skin manifestations, hypergammaglobulinemia, and positive Coombs test were recorded in a percentage of patients in the present series. Finally, we show the common T FH immunophenotype in both diseases and describe some patients who may switch from AITL to PTCL-F over time.
Altogether, these morphologic and phenotypic similarities and our observation of 3 patients in this series disclosing typical clinical and pathologic features of AITL at initial presentation and PTCL-F in other sequential biopsies, support a relationship between PTCL-F and AITL. Therefore, in agreement with a recent case report, 3 it might be tempting to speculate that, in at least some cases, PTCL-F could represent a peculiar stage of AITL in which neoplastic cells remain located within the B-cell follicles as highlighted by PD-1, CXCL13, and ICOS stainings. This hypothesis would imply several differences especially in terms of cytokine secretion capacities that would explain why the bona fide clinical, biologic, and histologic features of AITL are lacking in most PTCL-F (such as marked polymorphous infiltrates and florid hyperplasia of high-endothelial venules). This would also imply that the criteria used to define AITL should be reviewed, including cases without the constellation of clinical symptoms and pathologic features of AITL observed in its classic form. This hypothesis may be also supported by the observation that a proportion of T FH -derived PTCL-u shows at least some pathologic and/or clinical features of AITL. 8, 11, 30 Interestingly, EBV was observed in 68% of the PTCL-F tested cases with a pattern reminiscent of B-immunoblasts, a finding closer to that reported in most AITL than in PTCL-u. 2, 25, 44 Whether the presence of EBV should be regarded as an initiating event in PTCL-F, as it has been proposed for AITL, 10 is questionable. Therefore, our findings may suggest that at least some PTCL-F cases may reflect the broad morphologic spectrum of AITL and/or the lack of precise criteria for distinguishing borderline cases between PTCL-u, PTCL-F, and AITL. However, it cannot be formally excluded that AITL and PTCL-F represent distinct subtypes that, despite a common derivation from T FH cells, differ according to some oncogenic alterations.
Translocations of ITK on chromosome 5q33 and SYK on 9q22 which result in an ITK-SYK fusion transcript were observed in 4 patients of the present series, but have not been reported in 32 AITL cases investigated by FISH. 12, 35 ITK belongs to a group of 5 related kinases comprising the Tec family and plays a role in T cell development, differentiation, and T-cell receptor signaling. 45 SYK is a nonreceptor protein tyrosine kinase that functions as a key regulator of multiple signal transduction pathways. 4 In comparison with ITK, the translocation of SYK has already been shown in myelodysplastic syndromes. 22 The biologic significance of this translocation and its specificity remain unclear, and studies aiming to investigate the genetic abnormalities of PTCL-F compared with AITL are needed. Interestingly, overexpression of SYK has been recently recorded in most of the PTCL-u and AITL, independent of ITK-SYK translocation, suggesting alternative alterations resulting in the involvement of SYK pathway. 12 Whatever their relationship with other PTCL entities is, the peculiar histologic appearance of PTCL-F generates a list of differential diagnoses. PTCL with follicular growth pattern should be distinguished from reactive conditions and some B-cell lymphomas. At lowpower magnification, nodular growth pattern could be mistaken as a FL. Follicles in both diseases have decreased numbers of tingible body macrophages, attenuated mantle zone, and neoplastic cells could be both BCL-6 and CD10 positive. Lack of cytologic characteristics of centrocytes, abundant clear cytoplasm, and expression of T-cell markers in addition to CXCL13, PD-1, and/or ICOS argue for a diagnosis of PTCL. Other cases with large irregular nodules should be distinguished from a reactive process, specially PTGC, or nodular lymphocyte predominant Hodgkin lymphoma and other small B-cell lymphomas such as mantle cell lymphomas and marginal zone lymphomas. Immunohistochemistry showing aggregates of atypical medium-sized T cellssometimes with an abnormal T-cell phenotype-within the follicles and salient morphology of background B-cell infiltrates could help in making a correct diagnosis. T FH markers are useful to highlight the presence of aggregates of atypical T cells in hyperplastic follicles.
In conclusion, our study shows that, in agreement with the distribution of the neoplastic cells within zones of the B-cell follicle, the subgroup of PTCL with follicular growth pattern derives from T FH cells. It also indicates that at least some of them may present with the clinical and pathologic features of AITL. These findings may support a possible link between PTCL-F and AITL. In routine practice, immunohistochemistry with T FH markers is mandatory to distinguish these lymphomas from reactive lymphoid hyperplasia and some B-cell lymphomas. The biologic significance of the association with t(5;9) warrants further study.
